APOE and Alzheimer disease: Qrisk2, a holistic score for cardiovascular disease risk, was associated with specific biomarkers of AD and clinical progression of the disease.3 APOE ε4 non-carrier participants with prodromal AD (early/late mild cognitive impairment (MCI)) and higher levels of cardiovascular risk exhibited greater Aβ deposition and pronounced glucose hypometabolism compared with low cardiovascular risk individuals.3 This demonstrates the significance of cardiometabolic risk factors on AD progression independent of APOE ε4 status.